Academic research study
Have You Used GLP-1 Medications for Weight Loss?
Share your experiences.
Contribute to research.
The research
About the study
This is an exploratory study that aims to understand people’s experiences of using GLP-1 medications (weight-loss injections) and how these treatments fit into everyday life, decision-making, and wellbeing. By gathering personal accounts, it is anticipated that the findings will contribute to a more nuanced and human-centred understanding of weight-loss injections and their wider implications. ​
The research is being conducted by Tamsin Scott, a PhD researcher in Marketing at The University of Leeds Business School, specialising in consumer behaviour and psychology. She is currently working towards a PhD under the supervision of Dr Maximilian Gerrath (Associate Professor of Marketing) and Professor Alessandro Biraglia (Professor of Marketing and Behavioural Science).
Eligibility
Who can participate?
I’d love to speak with you about your experiences if you’re aged 18 or over and are currently using, or have previously used, a GLP-1 medication approved for weight management in the United Kingdom. This includes Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide). To take part, you’ll need to be living in the UK.
Participation
What does participation involve?
Participation involves taking part in a one-to-one interview conducted via Microsoft Teams, lasting approximately 30 to 60 minutes. The interview will be semi-structured, meaning some questions will guide the discussion while also allowing you to talk freely and explore topics in more depth if you wish. Some questions may require brief responses, while others invite more detailed reflection. Your participation will help contribute to a broader understanding of the research topic.
Considerations
What are the benefits and
disadvantages of participating?
While there may be no direct personal benefit, many people find it meaningful to share their experiences and reflect on their journey with weight-loss injections. Your insights will contribute to a better understanding of how these treatments are experienced in everyday life and help inform more supportive perspectives on GLP-1 use. The main consideration is the time commitment for the interview, which will last around 30 to 60 minutes. Every effort will be made to accommodate your schedule when arranging the interview.
Research ethics
Is this research being conducted ethically?
Yes. This study has received ethical approval from The University of Leeds (ethical approval ID: BESS+FREC 2025-3634). Research ethics are taken very seriously, and the study will be conducted in line with this approval and established ethical standards for academic research. This includes, but is not limited to, ensuring informed consent, protecting participant anonymity, handling data securely, and respecting participants’ right to withdraw from the study.
Getting involved
How can I get involved?
If you meet the eligibility criteria and are interested in taking part, please email the researcher at bn13tjs@leeds.ac.uk.​​
After you get in touch, you will be sent the Participant Information Sheet and Consent Form via DocuSeal (with a copy also attached to the email). These documents provide full details about the study and what participation would involve. If you decide to proceed, you can sign the Consent Form electronically via DocuSeal. Once completed, the researcher will countersign the form, return a copy to you for your records, and arrange a convenient interview time. Participation is entirely voluntary, and choosing not to take part will have no negative consequences.